CHAIR
:
SPEAKER
(S):
Elizabeth Bailey, Principal, Commons Capital
Bala Manian, PhD, CEO, ReaMetrix Inc.
Peter Kaspar, PhD, Head of Molecular Biology Business Unit, BioMerieux SA
Mark Perkins, MD, Chief Scientific Officer, Foundation for Innovative New Diagnostics
Description
Little has been done to address the current severe shortage of effective and appropriate diagnostics for health conditions that burden the developing world because of, in part, a lack of clear articulation of the specific needs, potential impact, performance characteristics and perceived market limitations. Presented data is based on recent quantitative needs assessment focused on those health conditions that have the greatest impact on the developing world.
Objectives:
Articulate the priority needs and potential health impact of diagnostic tools for the developing world.
Provide guidance to diagnostic tool and technology developers on the required performance and user requirements of new diagnostic tools to achieve a health impact.
Initiate discussions on defining novel approaches to creating sustainable diagnostic solutions for the developing world.